CClinicalTrials.gg
Status unknownNCT03308227Updated Oct 12, 2017

Plasma and Lung Tissue Concentrations of Linezolid in Septic Shock Patients

An observational study in Septic Shock, sponsored by Southeast University, China. Status unknown. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-12.

Sponsored by Southeast University, China · Observational

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
46
Ages
19 Years to 75 Years
Sex
All
01

Study summary

The study measures the plasma and bronchoalveolar lavage fluid concentrations of linezolid in septic shock patients comparing with non-septic shock patients to confirm the impact of septic shock on PK/PD of linezolid.

Read the detailed description

A wide array of pathophysiological changes occurring in severe sepsis and septic shock patients may influence antibiotics' pharmacokinetic (PK) properties. The pharmacokinetics and tissue distributions of linezolid achieving effective concentrations are key factors of successful clinical outcomes. To the best of our knowledge, no observational clinical studies are available on the plasma and bronchoalveolar lavage fluid concentrations of linezolid in septic shock patients. Severe pneumonia patients known or suspected to be caused by Gram-positive pathogens will be considered eligible for the study when the attending physician prescribed linezolid as treatment. The plasma and bronchoalveolar lavage fluid concentrations of linezolid are measured in each group at steady state. In an in vitro PK Model, concentration-time curve is drawn to calculate %T>MIC or AUC0-24h/MIC. Linezolid pharmacodynamics evaluation should be based on bacterial eradication and clinical outcomes.

02

Conditions studied

  • Septic Shock

Keywords

  • Linezolid; PK/PD; Septic shock
03

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed as severe pneumonia requiring mechanical ventilatory support.

Inclusion criteria

  1. between 18 years old and 75 years old;
  2. Admitted to the ICU;
  3. Expectation, in the opinion of the investigator, that the patients' infection will require ICU stay more than 3 days;
  4. Patients diagnosed as severe pneumonia requiring mechanical ventilatory support;
  5. Severe pneumonia known or suspected to be caused by Gram-positive pathogens;
  6. Expected to treat with linezolid.

Exclusion criteria

Exclusion Criteria:

  1. Unable to take bronchoalveolar lavage via bronchofiberscopy;
  2. Allergy, hypersensitivity or a serious reaction to linezolid;
  3. Treatment with linezolid during the previous 72 hours;
  4. Pregnancy.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
46 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental Group

    septic shock patients;

  • Conrol Group

    non-septic shock patients;

05

What researchers measure

Primary outcomes

  1. The plasma and bronchoalveolar lavage fluid concentrations of linezolid

    The plasma and bronchoalveolar lavage fluid concentrations of linezolid are measured in each group at steady state

    Time frame: Baseline, Day 3, Day 7

Secondary outcomes

  1. Bacterial eradication

    blood and respiratory secretions culture

    Time frame: Baseline, Day 3, Day 7

Other outcomes

  1. mortality

    the outcomes of the patients will be recorded

    Time frame: 28-mortality and 60-mortality

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03308227
Lead sponsor
Southeast University, China
Collaborators
Cttq
Responsible party
Jingyuan,Xu (chief doctor, Southeast University, China) — Principal investigator
First posted
Oct 12, 2017
Start date
Oct 20, 2017 (estimated)
Primary completion
Feb 28, 2018 (estimated)
Completion
Apr 30, 2018 (estimated)
Last update
Oct 12, 2017

Study contacts

Haibo Qiu, PHD
Contact
haiboq2000@163.com
8602583262550
Yingzi Huang, PHD
Contact
Yz_huang@126.com
8602583262550
Yingzi Yingzi, PHD
principal investigator · Southeast University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion